Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE Stok Raporu

Piyasa değeri: ₹1.7b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Lotus Eye Hospital and Institute Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lotus Eye Hospital and Institute.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Healthcare kazanç büyümesi26.2%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Lotus Eye Hospital and Institute yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:LOTUSEYE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/202448522N/AN/AN/A
3/31/202448229057N/A
12/31/202348535N/AN/AN/A
9/30/202348640-157N/A
6/30/202347741N/AN/AN/A
3/31/2023470411344N/A
12/31/202246440N/AN/AN/A
9/30/2022459421369N/A
6/30/202244946N/AN/AN/A
3/31/202238930-344N/A
12/31/202138936N/AN/AN/A
9/30/2021372323749N/A
6/30/202133520N/AN/AN/A
3/31/2021324162327N/A
12/31/2020300-5N/AN/AN/A
9/30/2020301-14826N/A
6/30/2020335-6N/AN/AN/A
3/31/2020406112650N/A
12/31/201942021N/AN/AN/A
9/30/201941520N/AN/AN/A
6/30/201940111N/AN/AN/A
3/31/20193847-542N/A
12/31/20183827N/AN/AN/A
9/30/20183819N/AN/AN/A
6/30/201838414N/AN/AN/A
3/31/201838017N/A58N/A
12/31/20173738N/AN/AN/A
9/30/20173594N/AN/AN/A
6/30/20173506N/AN/AN/A
3/31/20173404N/A30N/A
12/31/20163307N/AN/AN/A
9/30/20163247N/AN/AN/A
6/30/20163140N/AN/AN/A
3/31/20163111N/A34N/A
12/31/2015311-5N/AN/AN/A
9/30/2015315-6N/AN/AN/A
6/30/2015308-14N/AN/AN/A
3/31/2015302-20N/A24N/A
12/31/2014298-12N/AN/AN/A
9/30/2014290-9N/AN/AN/A
6/30/20142891N/AN/AN/A
3/31/20142880N/A44N/A
12/31/20132874N/AN/AN/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if LOTUSEYE's forecast earnings growth is above the savings rate (6.7%).

Kazançlar ve Piyasa: Insufficient data to determine if LOTUSEYE's earnings are forecast to grow faster than the Indian market

Yüksek Büyüme Kazançları: Insufficient data to determine if LOTUSEYE's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if LOTUSEYE's revenue is forecast to grow faster than the Indian market.

Yüksek Büyüme Geliri: Insufficient data to determine if LOTUSEYE's revenue is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if LOTUSEYE's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin